An Efficient Development Paradigm for Biosimilars

DOI: 10.1007/s40259-019-00371-4
BioDrugs, 2019, 33, 603-611.

#	Paper	IF	Citations
22	Delivering on the Promise of Biosimilars. *BioDrugs*, **2019**, 33, 599-602	7.9	5
21	Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. *Drug Discovery Today*, **2020**, 25, 1910-1910	8.8	13
20	[Biosimilars in the European Union: current situation and challenges]. *Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz*, **2020**, 63, 1365-1372	7.5	1
19	The controversy around technical standards for similar biotherapeutics: barriers to access and competition?. *Pharmacoepidemiology and Drug Safety*, **2020**, 29, 1518-1522	2.6	2
18	Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. *Journal of Clinical Oncology*, **2020**, 38, 1070-1080	2.2	9
17	The Path Towards a Tailored Clinical Biosimilar Development. *BioDrugs*, **2020**, 34, 297-306	7.9	12
16	Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study. *Biologicals*, **2021**, 69, 30-37	1.8	2
15	Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. *Pharmaceuticals*, **2021**, 14,	5.2	2
14	Evolving Biosimilar Clinical Requirements: A Qualitative Interview Study with Industry Experts and European National Medicines Agency Regulators. *BioDrugs*, **2021**, 35, 351-361	7.9	
13	Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance. *BioDrugs*, **2021**, 35, 379-387	7.9	1
12	Challenges Faced by the Biopharmaceutical Industry in the Development and Marketing Authorization of Biosimilar Medicines in BRICS-TM Countries: An Exploratory Study. *Pharmaceutical Medicine*, **2021**, 35, 235-251	2.3	3
11	Extrapolation: Experience gained from original biologics. *Drug Discovery Today*, **2021**, 26, 2003-2013	8.8	3
10	Overcoming Barriers to Biosimilar Adoption: Commentary on "Cost to Medicare of Delayed Adalimumab Biosimilar Availability". *Clinical Pharmacology and Therapeutics*, **2021**,	6.1	
9	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. *Drugs*, **2021**, 81, 1859-1879	11.1	3
8	Biosimilarity and Interchangeability of Biologic Drugs-General Principles, Biophysical Tests, and Clinical Requirements to Demonstrate Biosimilarity. **2020**, 109-124		
7	Biosimilar development and review process in the BRICS-TM countries: proposal for a standardized model to improve regulatory performance.. *Expert Review of Clinical Pharmacology*, **2022**,	3.8	0
6	Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. *BioDrugs*,	7.9	0

5	Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One. *BioDrugs*,	7.9
4	The Role of PD Biomarkers in Biosimilar Development - To Get the Right Answer One Must First Ask the Right Question.	1
3	Pharmacodynamic Biomarkers for Biosimilar Development and Approval: A Workshop Summary.	1
2	A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal Antibodies. **2023**, 113, 108-123	1
1	Cerebrolysin in the treatment of cognitive impairment. **2023**, 123, 20	0